GI Innovation, Inc.
358570.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$543.37B
Close$
$-2865.60
133.9% downside
Current Fair Value
133.9% downsideOvervalued by 133.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $543.37 Billion |
|---|---|
| Enterprise Value | $516.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-556.15 |
| Beta | 0.44 |
| Outstanding Shares | 64,332,183 |
Return
| Return on Equity | -40.50% |
|---|---|
| Return on Assets | -37.09% |
| Return on Invested Capital | -44.66% |
Valuation & Multiples
| P/E Ratio | -13.79 |
|---|---|
| PEG | -29.98 |
| Price to Sales | 99.53 |
| Price to Book Ratio | 5.63 |
| Enterprise Value to Revenue | 93.85 |
| Enterprise Value to EBIT | -11.83 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About GI Innovation, Inc.
82 employeesGI Innovation, Inc. specializes in the research and creation of biopharmaceutical products. Its current developmental portfolio features drug candidates G-101, G-102, G-301, and G-108. Founded by Jang Myoung-ho on July 19, 2017, the company's main operations are situated in Seoul, South Korea.